Pharma
Catalent Inc <CTLT.N>: Profits of 69 cents per share anticipated for fourth quarter
- February 03, 2023 06:11 AM PST | Reuters

3 February 2023 02:11 p.m. All figures in US dollars. Catalent Inc is expected to show a decrease in its fourth quarter earnings to 69 cents per share according to the mean Refinitiv estimate from
Tenax Therapeutics Announces Pricing Of Approximately $15.6 Million Public Offering
- February 03, 2023 05:23 AM PST
- Reuters
Regeneron profit beats estimates on Dupixent strength
- February 03, 2023 05:01 AM PST
- Reuters

Immunovant Reports Cash Balance Of About $433 Mln As Of December 31
- February 03, 2023 04:49 AM PST | Reuters
Feb 3 (Reuters) - Immunovant Inc: * IMMUNOVANT REPORTS FINANCIAL RESULTS AND RECENT BUSINESS UPDATES FOR THE QUARTER ENDED DECEMBER 31, 2022 * IMMUNOVANT INC - CASH BALANCE OF ABOUT $433 MILLION AS OF
Read More...
Twist Bioscience Reports Fiscal First Quarter 2023 Results
- February 03, 2023 04:47 AM PST | Reuters
Feb 3 (Reuters) - Twist Bioscience Corp: * TWIST BIOSCIENCE REPORTS FISCAL FIRST QUARTER 2023 FINANCIAL RESULTS * Q1 EARNINGS PER SHARE VIEW $-1.13, REVENUE VIEW $54.1 MILLION -- REFINITIV IBES DATA *
Read More...
Immunovant Inc <IMVT.O>: Losses of 49 cents announced for third quarter
- February 03, 2023 04:46 AM PST | Reuters
3 February 2023 12:46 p.m. All figures in US dollars. The loss announced by Immunovant Inc in the third quarter were lower than the Refinitiv mean estimate of losses. The company reported losses of -
Read More...
Immunovant Inc reports results for the quarter ended in December - Earnings Summary
- February 03, 2023 04:46 AM PST | Reuters
* Immunovant Inc reported a quarterly adjusted loss of 49 cents per share for the quarter ended in December. The mean expectation of eight analysts for the quarter was for a loss of 39 cents per
Read More...
Oragenics Regains Compliance With NYSE American
- February 03, 2023 04:45 AM PST | Reuters
Feb 3 (Reuters) - Oragenics Inc: * ORAGENICS, INC. REGAINS COMPLIANCE WITH NYSE AMERICAN Source text for Eikon: Further company coverage:
Read More...
Vyant Bio Inc Says Under Cash Preservation Plan Of Jan 31, Co Sees To Incur About $1.4 Mln For Employee Termination-Related Costs In Q1, Q2 Of 2023
- February 03, 2023 04:42 AM PST | Reuters
Feb 3 (Reuters) - Vyant Bio Inc: * VYANT BIO INC - UNDER CASH PRESERVATION PLAN OF JAN 31, CO SEES TO INCUR ABOUT $1.4 MILLION FOR EMPLOYEE TERMINATION-RELATED COSTS IN Q1 AND Q2 OF 2023 * VYANT BIO
Read More...
Merck Says Keytruda Plus Chemotherapy Met Primary Endpoint Of Progression-Free Survival As First-Line Therapy For Advanced Or Recurrent Endometrial Carcinoma
- February 03, 2023 04:40 AM PST | Reuters
Feb 3 (Reuters) - Merck & Co Inc: * MERCK’S KEYTRUDA® (PEMBROLIZUMAB) PLUS CHEMOTHERAPY MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AS FIRST-LINE THERAPY FOR ADVANCED OR RECURRENT
Read More...
Regeneron Sees 2023 Capital Expenditures Of $825-$950 Mln
- February 03, 2023 04:38 AM PST | Reuters
Feb 3 (Reuters) - Regeneron Pharmaceuticals Inc : * REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS * REGENERON PHARMACEUTICALS - SUPPLEMENTAL BLA FOR EYLEA TO
Read More...
Neurocrine Biosciences Inc <NBIX.O>: Profits of $1.14 per share anticipated for fourth quarter
- February 03, 2023 04:33 AM PST | Reuters
3 February 2023 12:33 p.m. All figures in US dollars. Neurocrine Biosciences Inc is expected to show an increase in its fourth quarter earnings to $1.14 per share according to the mean Refinitiv
Read More...
Neurocrine Biosciences Inc expected to post earnings of $1.14 a share - Earnings Preview
- February 03, 2023 04:32 AM PST | Reuters
* Neurocrine Biosciences Inc is expected to show a rise in quarterly revenue when it reports results on February 6. * The San Diego California-based company is expected to report a 31.1% increase in
Read More...